I would generally agree with this @Onemillmin. The agreement for the 20 million rapid antigen tests not only provides a potential financial windfall for Atomo, but also fosters a cultural change in point-of-care testing; this can only be considered a win for Atomo. I look forward to the day when we see the approval of FebriDX (which has taken seemingly forever); the growth of the HIV market (we are being introduced to +135 countries); growth in the US market (via Bondi Partners, with shares opening in April 2022 at $0.40c); and registering and manufacturing of non-blood based testing (currently sitting with IP Australia).
Atomo's trajectory from mid-2020 has been buffeted by general bad luck associated with approval delays - perhaps its a marker of the medical market. Let's hope this year is different. The company certainly still has the backing of large long-term shareholders, such as Ellerston Capital, Perennial Value Management, and the Global Health Investment Fund.
- Forums
- ASX - By Stock
- AT1
- Media Update
Media Update, page-1605
-
- There are more pages in this discussion • 241 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AT1 (ASX) to my watchlist
|
|||||
Last
2.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $17.25M |
Open | High | Low | Value | Volume |
2.8¢ | 2.9¢ | 2.7¢ | $10.03K | 365.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 668702 | 2.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.8¢ | 11840 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
7 | 668702 | 0.027 |
5 | 514425 | 0.026 |
5 | 315000 | 0.025 |
2 | 61707 | 0.024 |
1 | 393000 | 0.023 |
Price($) | Vol. | No. |
---|---|---|
0.028 | 11840 | 2 |
0.029 | 472024 | 8 |
0.030 | 1292320 | 15 |
0.031 | 466110 | 6 |
0.032 | 200000 | 1 |
Last trade - 16.10pm 24/06/2024 (20 minute delay) ? |
Featured News
AT1 (ASX) Chart |